Dominari Holdings Inc. (DOMH)

NASDAQ: DOMH · IEX Real-Time Price · USD
+0.07 (1.83%)
Jan 27, 2023, 4:00 PM EST - Market closed
Market Cap 21.39M
Revenue (ttm) n/a
Net Income (ttm) -20.77M
Shares Out 5.49M
EPS (ttm) -3.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,369
Open 3.96
Previous Close 3.83
Day's Range 3.80 - 3.99
52-Week Range 3.02 - 10.20
Beta 0.92
Analysts n/a
Price Target 16.32 (+318.46%)
Earnings Date Mar 27, 2023

About DOMH

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1967
Employees 4
Stock Exchange NASDAQ
Ticker Symbol DOMH
Full Company Profile

Financial Performance

Financial Statements


Dominari Holdings Provides Update on Share Repurchase Program

NEW YORK , Jan. 27, 2023 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase ...

2 days ago - PRNewsWire